Arcturus Therapeutics (NASDAQ:ARCT) Cut to Strong Sell at Wall Street Zen

Posted by Stanley Muller on Aug 4th, 2026

Wall Street Zen cut shares of Arcturus Therapeutics (NASDAQ:ARCT – Free Report) from a sell rating to a strong sell rating in a report released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.25.

Check Out Our Latest Research Report on ARCT

Arcturus Therapeutics Trading Up 4.2%

Arcturus Therapeutics stock opened at $6.00 on Friday. Arcturus Therapeutics has a 12 month low of $5.50 and a 12 month high of $24.17. The stock has a fifty day simple moving average of $6.87 and a two-hundred day simple moving average of $7.41. The firm has a market cap of $170.54 million, a price-to-earnings ratio of -2.14 and a beta of 2.37.

Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last announced its quarterly earnings results on Friday, May 8th. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.08. Arcturus Therapeutics had a negative return on equity of 36.55% and a negative net margin of 143.80%.The firm had revenue of $2.06 million for the quarter, compared to the consensus estimate of $6.30 million. On average, equities research analysts forecast that Arcturus Therapeutics will post -3.99 EPS for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

Hedge funds have recently bought and sold shares of the company. Osaic Holdings Inc. boosted its position in Arcturus Therapeutics by 51.8% in the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 738 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Arcturus Therapeutics by 163.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 2,586 shares during the period. Mercer Global Advisors Inc. ADV purchased a new position in shares of Arcturus Therapeutics in the fourth quarter worth approximately $64,000. Intech Investment Management LLC purchased a new position in shares of Arcturus Therapeutics in the fourth quarter worth approximately $70,000. Finally, CANADA LIFE ASSURANCE Co boosted its holdings in shares of Arcturus Therapeutics by 65.1% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 12,009 shares of the biotechnology company’s stock worth $73,000 after buying an additional 4,737 shares during the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

(Get Free Report)

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.